A new cancer vaccine developed by three Russian research units will be tested in clinical trials for patients with malignant lung cancer and small cell lung cancer first.
 |
| Russia is promoting clinical trials of a cancer vaccine. Illustrative photo. (Source: MedTour) |
The above information is Director of the National Center for Epidemiology and Microbiology named after NF Gamaley, Mr. Alexander Gintsburg said on October 12.
The choice of disease is related to many factors, according to Mr. Gintsburg, as small cell carcinoma is one of the most common malignant cancers, killing about 1.3 million people each year. In addition, malignant tumors are technically easier to treat, because they are only superficial.
The vaccination process will be different from previous drug trials, the director added, adding that mass testing on large numbers of people is not possible due to the individualized nature of the product.
The three entities developing the Russian cancer vaccine are the NF Gamaley State Research Center of Epidemiology and Microbiology, the PA Herzen Moscow Scientific Research Institute of Oncology and the NN Blokhin National Medical Research Center on Oncology. The project is funded by the Russian state.
In early June, Russian Health Minister Mikhail Murashko said that the results of preclinical studies of the cancer vaccine are expected only by the end of this year, after which clinical trials will begin.
However, by September, preclinical trials were completed. Therefore, the Director General of the National Medical Research Center of Radiology under the Ministry of Health of Russia, Academician of the Russian Academy of Sciences Andrei Kaprin announced that the first phase of clinical trials will begin after receiving approval from the Ministry of Health of the Russian Federation.
Source: https://baoquocte.vn/nga-xuc-tien-thu-nghiem-lam-sang-vaccine-ngua-ung-thu-289931.html
Comment (0)